Expression of Programmed Death Ligand-1 (PD-L1) in Nasopharyngeal and Hyypopharyngeal Carcinoma

Not yet recruiting

• Conditions: Nasopharyngeal and Hypopharyngeal Carcinoma

• Registration Number: NCT05595265
• Lead Sponsor: Sohag University

Brief Summary

Head and neck tumors comprise heterogeneous neoplasms that arise from surface epithelium of different anatomic subsites in head and neck region such as oral cavity, oropharynx, larynx and hypopharynx. Nasopharyngeal and hypopharyngeal carcinomas represent 0.26 % of all cancers in Egypt. Tobacco exposure and alcohol dependence, and infection with oncogenic viruses such as human Papilloma virus (HPV) are among the risk factors for development of these tumors. Currently, the main treatment of nasopharyngeal and hypopharyngeal carcinomas is radio-chemotherapy based in histological type, grade and stages of the tumors

Tumor infiltrating lymphocytes (TILs) are considered as cornerstone in cancer immunotherapy and as a biomarker with effectiveness predictive value. The intensity and quality of immune cells, especially lymphocytes, in tumor microenvironment are strongly related to the outcome of immune checkpoint blockade therapy .

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2022-10
• Study First Submitted: 2022-10-23
• Study First Submitted QC: 2022-10-23
• Last Update Submitted: 2022-10-23
• Study First Posted: 2022-10-26
• Last Update Posted: 2022-10-26
• Study Start: 2022-11
• Primary Completion: 2023-11
• Study Completion: 2023-11

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Patients with nasopharyngeal and hypopharyngeal carcinomas who underwent diagnostic biopsies.

Read More

Exclusion Criteria

• Patients received chemotherapy or radiotherapy.
• Patients with insufficient clinical data.
• Specimens with extensive necrosis
• Tiny specimens which are insufficient for accurate diagnosis.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
expression of programmed death ligand-1 (PD-L1) in nasopharyngeal and hypopharyngeal carcinoma	12 months	evaluate expression of PD-L1 in nasopharyngeal and hypopharyngeal carcinomas and to correlate its expression to different clinical and histopathological parameters to address its prognostic value.

Trial Locations

Locations (1)

Sohag University Hospital; 🇪🇬 Sohag, Egypt